Date and Time:

Thursday, August 5, 2021
4:00-5:30 pm EST

Session Description:

Non-Hodgkin’s lymphoma can be divided into two groups: B cell lymphomas and T cell lymphomas. T Cell lymphomas account for approximately 10-15% of all Non-Hodgkin lymphoma cases in Canada. T Cell lymphomas are a type of cancer that affects the T lymphocytes, which play an important role in the immune response. There are many subtypes of T Cell lymphomas; some are more common while some are more rare.

Common types of T cell lymphomas include Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL). Though both are T Cell lymphomas, they have unique clinical courses and treatment options. This two-part presentation will provide patients with information about these specific lymphoma subtypes, providing both background knowledge as well as updates on new research and novel treatment options available for Canadian patients.


Dr. Eugenia Piliotis, MD, MPH
Hematologist, Sunnybrook Health Sciences Centre, Toronto, Canada
Associate Professor, University of Toronto, Canada

Dr. Eugenia Piliotis is a hematologist at Sunnybrook Health Sciences Centre and is currently an Associate Professor at the University of Toronto. In addition to her clinical duties, Dr. Piliotis has held numerous leadership positions. She is currently the Chair of the Royal College Hematology specialty committee and has held many leadership positions with the University of Toronto Department of Medicine.  She dedicates her time and efforts to research related to cutaneous lymphomas, is involved in creating hospital guidelines, and is highly published on this subtype.

Dr. Michael Crump, MD
Hematologist, Princess Margaret Cancer Centre, Toronto, Canada
Professor, University of Toronto, Canada

Dr. Michael Crump is a hematologist in the Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, and Professor of Medicine at the University of Toronto. His clinical and research interests are primary and second-line therapy of lymphoid malignancies, investigation of novel therapies, and autologous stem cell transplantation. He is currently the Co-Chair of the Hematology Disease Site Group and the Lymphoma Working Group Chair for the Canadian Cancer Trials Group (CCTG). He has been involved in clinical research related to peripheral t-cell lymphomas and dedicates his time to this patient population.


About adam